Rachel B Jones

Summary

Country: UK

Publications

  1. doi request reprint Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
    Fausta Catapano
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge University, Hills Road, UK
    Nephrol Dial Transplant 25:3586-92. 2010
  2. doi request reprint A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
    Rachel B Jones
    Renal Unit, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 60:2156-68. 2009
  3. ncbi request reprint Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
  4. doi request reprint Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 64:3760-9. 2012
  5. pmc The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
    Helena Marco
    Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK
    BMC Musculoskelet Disord 15:178. 2014
  6. ncbi request reprint What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Rachel B Jones
    Renal Unit, Vasculitis and Lupus Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge CB2 OQQ, UK
    Curr Opin Rheumatol 21:256-61. 2009
  7. pmc Progress in treatment of ANCA-associated vasculitis
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB20QQ, UK
    Arthritis Res Ther 14:210. 2012
  8. doi request reprint Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid
    Thomas F Hiemstra
    Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, UK
    Nephron Clin Pract 116:c1-10. 2010

Detail Information

Publications8

  1. doi request reprint Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus
    Fausta Catapano
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge University, Hills Road, UK
    Nephrol Dial Transplant 25:3586-92. 2010
    ..We sought to assess the long-term efficacy and safety of rituximab in this patient subgroup...
  2. doi request reprint A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis
    Rachel B Jones
    Renal Unit, Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 60:2156-68. 2009
    ..This permitted comparison of rituximab dosing regimens, the value of continuing immunosuppression, and investigation of ANCA and B cell levels as re-treatment biomarkers...
  3. ncbi request reprint Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
    ..Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens...
  4. doi request reprint Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
    Rona M Smith
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Rheum 64:3760-9. 2012
    ..However, further relapse is common, and maintenance strategies are required. The aim of this study was to reduce relapse rates using a fixed-interval rituximab re-treatment protocol...
  5. pmc The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
    Helena Marco
    Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK
    BMC Musculoskelet Disord 15:178. 2014
    ..CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia...
  6. ncbi request reprint What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Rachel B Jones
    Renal Unit, Vasculitis and Lupus Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge CB2 OQQ, UK
    Curr Opin Rheumatol 21:256-61. 2009
    ..The precise role of MMF is under ongoing evaluation. This review provides an up-to-date summary of MMF and its use as remission induction and maintenance therapy for lupus nephritis...
  7. pmc Progress in treatment of ANCA-associated vasculitis
    Rona M Smith
    Department of Renal Medicine, Addenbrooke s Hospital, Hills Road, Cambridge CB20QQ, UK
    Arthritis Res Ther 14:210. 2012
    ..As rare diseases, treatment advances in vasculitis depend on international collaborative research networks both to establish an evidence base for newer agents and to develop recommendations for patient management...
  8. doi request reprint Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid
    Thomas F Hiemstra
    Lupus and Vasculitis Unit, Addenbrookes Hospital, Cambridge, UK
    Nephron Clin Pract 116:c1-10. 2010
    ....